Abstract

Evidence-based recommendations on lusutrombopag (Mulpleo) for treating severe thrombocytopenia in adults with chronic liver disease needing a planned invasive procedure.

Is this guidance up to date?

Next review: 2023

Guidance development process

How we develop NICE technology appraisal guidance